Andrew Lee is a founder and the CEO of Spot Biosystems, a company that is applying exosomes for drug therapies. Andrew supports LDV Partners as a part-time venture partner.
Andrew is the Founder of StartX Med, the Medical Accelerator of Stanford University and Stanford Hospital. Over 300 US hospitals, 3,500 clinics, and all 10 of the top 10 global pharmaceutical companies are paying customers / co-investors in StartX Med company products. At StartX, Andrew leads verticals in biotechnology, FDA/CLIA regulated products, and medical/pharma enterprise. To date, he has supported over 350 medical portfolio companies and 40+ FDA approvals in the biotech, med device, and digital health/ AI spaces with $3.5B+ in cumulative funding and since 2012. He is also the Founder and Managing Director of StartX-QB3 Labs, a joint medical science and engineering venture between Stanford’s StartX and UCSF’s QB3 programs. Andrew’s portfolio companies include Kodiak (Nasdaq:KOD), CAPP Medical (acquired by Roche), Freenome and Orca Bio. Andrew is also a Y Combinator alumnus, where he co-founded Clipboard Health, a leading healthcare staffing company that works with hospitals across the US. Within the Y Combinator community, Andrew has invested in a number of seed stage deals including Curative, one of the fastest growing COVID-19 screening companies in the US.
Andrew has published over 50 peer reviewed research manuscripts on the use of medical technologies in personalized medicine. His research has been supported by the FDA, Howard Hughes Medical Institute, Stanford Bio-X, and the American Heart Association, as well as a number of the top 10 global pharmaceutical companies. Andrew earned his M.D. and Ph.D. from Stanford University School of Medicine.